JPMorgan raised the firm’s price target on Amicus (FOLD) to $18 from $16 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect a December 2026 target versus 2025 previously.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Reports Strong Growth Amid Strategic Advances
- Strong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics
- Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Amicus Therapeutics Reports Strong Q2 2025 Growth
- Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating